Compare NG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NG | BLLN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 713 |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2002 | N/A |
| Metric | NG | BLLN |
|---|---|---|
| Price | $9.01 | $78.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $11.90 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 3.7M | 311.5K |
| Earning Date | 04-01-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $45.89 |
| Revenue Next Year | N/A | $30.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.26 | $61.96 |
| 52 Week High | $14.40 | $138.70 |
| Indicator | NG | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 53.54 |
| Support Level | $7.85 | $63.98 |
| Resistance Level | $10.61 | $83.20 |
| Average True Range (ATR) | 0.66 | 5.71 |
| MACD | 0.04 | 1.39 |
| Stochastic Oscillator | 46.78 | 68.67 |
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.